Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Leukemia: Lymphoid leukemia

A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

The purpose of this study is to learn about the safety of SD-101 and to find out what effects (both good and bad it has on B-cell Lymphoma when given along with low-dose radiation therapy.

Status: Accepting New Patients
Principal Investigator: Gordon

A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia

The purpose of this study is to evaluate the safety of an investigational drug, CB-839, and to determine the best dose to use for future studies.

Status: Accepting New Patients
Principal Investigator: Frankfurt

REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.

Status: Accepting New Patients
Principal Investigator: Victorson

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

The purpose of this study is to evaluate the effect of ABT-199 (GDC-0199)on CLL that has come back or did not get better after B-cell Receptor Signaling Pathway Inhibitor (BCR PI)treatment.

Status: Accepting New Patients
Principal Investigator: Ma

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors:Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations

Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Chae

A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

The purpose of this study is to find out what effects the combination of ofatumumab and alemtuzumab antibody therapy has on chronic lymphocytic leukemia (CLL).

Status: Accepting New Patients
Principal Investigator: Ma

A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the effects, both good and bad, that two different cancer treatments have on patients and their cancer. These treatments include combinations of the drugs rituximab, fludarabine, cyclophosphamide and ibrutinib.

Status: Accepting New Patients
Principal Investigator: Ma

A Randomized Phase III Study Of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (= 65 Years Of Age) with Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the safety (side effects) and effectiveness of the research drug ibrutinib to the standard treatment for your disease.

Status: Accepting New Patients
Principal Investigator: Ma

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Petrich

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD

The purpose of a phase 2 study is to determine the efficacy, safety and tolerability of intravenous bortezomib in patients with pulmonary GVHD after allogeneic HSCT.

Status: Accepting New Patients
Principal Investigator: Jain

A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic Malignancies

The purpose of this study is to find out the effects, good and bad, that EPZ-5676 has on patients and their cancer.

Status: Accepting New Patients
Principal Investigator: Altman

last updated: Thu - July 30, 2015 - 02:19 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.